Basilea & Roche to jointly study novel treatment for urothelial cancer
Category: #health  By Nikita Chaurasia  Date: 2019-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Basilea & Roche to jointly study novel treatment for urothelial cancer

The planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer.

Basilea Pharmaceutica Limited, a commercial stage biopharmaceutical company, has reportedly announced a partnership with Roche to discover a combination of Roches PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) and Basileas derazantinib for people suffering from urothelial cancer.

Chief Medical Officer of Basilea Pharmaceutica Ltd, Dr. Marc Engelhardt was reportedly quoted saying that the firm is delighted to collaborate with Roche as the looks forward to explore a unique targeted treatment approach which addresses the high medical need of patients suffering from urothelical cancer. The combination of atezolizumab and derazantinib is based on a sound scientific rationale. Moreover, derazantinib has the capacity to improve the response to atezolizumab's immune-checkpoint inhibition.

For the uninitiated, derazantinib is called a panFGFR kinase inhibitor as it is known to be an investigational orally administered small molecule inhibitor of the FGFR family of kinases with strong activity against FGFR1, 2, and 3.

According to a press release by Basilea Pharmaceutica, the planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer. Roche would provide clinical supply of atezolizumab and Basilea will be sponsoring the study, cite reliable sources.

Reportedly, the combination of inhibiting FGFR while, at the same time, improving T cell-mediated antitumor effects via CSF1R inhibition is potentially a promising new treatment approach in patients suffering from urothelial cancer.

For the record, urothelial cancer is the sixth most common cancer in the United States. These cancers begin in the urothelial cells that line the inside of the bladder. About 80,000 new cases of bladder cancer registered in the nation in the year 2017.

Sources familiar with the development claim that Basilea anticipates to begin a biomarker-driven multi-cohort phase 1/2 study by mid-2019.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
By Nikita Chaurasia

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric a...

Hyundai and Uber team up to develop all-electric flying taxis
Hyundai and Uber team up to develop all-electric flying taxis
By Nikita Chaurasia

In the midst of technological advancements increasing at a commendable pace, Uber’s flying taxi initiative seems to be edging closer to reality – the reality of establishing flying cars in the near future. The ride-hailing giant has appar...

BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
By Nikita Chaurasia

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the initiation of its SERENITY progr...